Skip to main content

Month: September 2022

Duchenne Muscular Dystrophy Market to Hit Sales of $1533.72 Million by 2028 | DMD Affects 250,000 Children Each Year | Gene Therapy is the Only effective Way to Treat DMD

Global Duchenne muscular dystrophy market was valued at USD 693.34 million in 2021, and it is expected to reach a value of USD 1,533.72 million by 2028, at a CAGR of more than 11.87% over the forecast period (2022–2028). Westford,USA, Sept. 28, 2022 (GLOBE NEWSWIRE) — There is an increasing demand for Duchenne muscular dystrophy (DMD) therapies, as the condition is still not curable. In the medical industry, there is growing interest in developing novel treatments that can help patients with DMD live longer and healthier lives. Characterized by progressive weakness and wasting of muscle, DMD affects approximately 1 in 5,000 male births in the Global Duchenne Muscular Dystrophy Market. Currently, there are no cures for DMD and most treatments only provide limited relief. However, developments in gene therapy and stem cell therapies...

Continue reading

Dental Laser Market to Hit Sales of $337.08 Million By 2028 | US is the Largest Export of Dental Lasers | SkyQuest Technology

Global Dental Laser Market was valued at USD 224.7 million in 2021, and the market size is estimated to reach USD 337.08 million by 2028, at a CAGR of 5.20% over the forecast period (2022–2028). Westford,USA, Sept. 28, 2022 (GLOBE NEWSWIRE) — The use of Global Dental Lasers Market has seen an increase in recent years, with patients benefiting from the greater accuracy and precision of the treatment. Many potential patients are put off by the high cost of laser therapy, but there are a number of dental laser clinics and providers in the global dental laser market that offer affordable options for those seeking treatments. Dentists at these clinics typically use either the DiLase 3 or 5 technologies, which deliver two different types of beams to a target area on teeth. The result is less pain and faster healing times, making dental...

Continue reading

Global N-Acetylcysteine Market to Generate Revenue of $4236.19 million by 2028 | Unclear Safety Profile of N-Acetylcysteine to Remain key Challenge

Global N-acetylcysteine market was valued at USD 1083.78 million in 2021 and is projected to attain a market value of USD 4236.19 million by 2028 at a CAGR of 21.50% during the forecast period, 2022–2028. Westford,USA, Sept. 28, 2022 (GLOBE NEWSWIRE) — N-Acetylcysteine market is widely known as a treatment for acetaminophen (Tylenol) poisoning and other serious illnesses, but its uses are expanding rapidly. Recent studies have shown that N-Acetylcysteine can be helpful in treatment of chronic pain, opioid addiction, major depressive disorder, and neurological disorders such as Parkinson’s disease. There are several reasons why N-Acetylcysteine market is becoming increasingly popular. First, it is a relatively safe and effective treatment option that offers relief from many common conditions. Second, it has minimal side effects...

Continue reading

Blepharoplasty Market to Hit Sales of $5.80 Billion by 2028 | 1.4 million Blepharoplasty Procedures Performed in 2021 | SkyQuest Technology

Global blepharoplasty market was valued at USD 3.91 billion in 2021, and it is expected to reach a value of USD 5.80 billion by 2028, at a CAGR of 5.8% over the forecast period (2022–2028). Westford, USA, Sept. 28, 2022 (GLOBE NEWSWIRE) — Blepharoplasty, or eyelid surgery, is on the rise due to increased demand from patients who want to look more natural. This procedure can help correct drooping or heavy eyelids, giving person a more youthful appearance. It is also possible to restore natural upper lid shape, which can improve overall appearance of an individual. As a result, there is an increasing demand for the procedure in the global blepharoplasty market. As per SkyQuest analysis, there has been an 83% increase in blepharoplasty procedures from 2012 to 2022. Part of the reason for this increase is likely because more people...

Continue reading

Global Cosmetic Surgery Market to Hit Sales of $59.69 Billion by 2028 | US and Brazil Perform Over 28% of the Global Cosmetic Procedures

Global cosmetic surgery market size was valued at USD 45.85 billion in 2021, and it is expected to reach a value of USD 59.69 billion by 2028, at a CAGR of more than 3.84% over the forecast period (2022–2028). Westford, USA, Sept. 28, 2022 (GLOBE NEWSWIRE) — According to SkyQuest, the demand for cosmetic surgery market is on the rise, with more women earning more money and seeking to enhance their appearance. For instance, the median household income for women was $912 in 2012, which was 5 times lower than men. However, the scenario has changed and the income has exceeded $10,000 in 2021 in the US. Furthermore, many women are starting to feel more confident in themselves and want to reflect this confidence outward by enhancing their appearance. It has also been said that “more Caucasian women are undergoing plastic surgery because...

Continue reading

Valiant Eagle Inc. (OTC: PSRU) Significantly Increases Its Equity Stake in Sumer Technologies, Inc., as the Ride-Sharing Company Readies Its Much Anticipated Innovative Zumr App For Q1 2023 U.S. Launch

LOS ANGELES, Sept. 28, 2022 (GLOBE NEWSWIRE) — Valiant Eagle, Inc. (OTC: PSRU) is proud to announce that the company has tripled its equity ownership in the ride-sharing company, Sumer Technologies, Inc. Valiant Eagle acquired its initial stake in Sumer back in October 2021, as a way to gain exposure to the ever-growing ride-sharing industry. Valiant Eagle’s increased ownership stake in Sumer comes as the multi-faceted app developer diligently works on the development of several new applications. The first app Sumer is focused on launching is called Zumr Rideshare. Zumr app is slated for launch in the United States during the first quarter of 2023 and will be available on Android and iOS devices. Sumer is also planning to roll out the Zumr app in Africa during the third quarter of 2023.  Further expansion across additional international...

Continue reading

Financial 15 Split Corp. Preferred Share Rate Increase

A high quality portfolio consisting of 15 North American Financial Services Companies TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (the “Company”) is pleased to announce the Preferred Share dividend rate for the fiscal year beginning December 1, 2022. Based on current market rates for preferred shares with similar terms, monthly payments to FTN.PR.A will be $0.06250 per share for an annual yield of 7.50% on their $10 redemption value. This is an increase of three quarters of one percent over the current rate. The Company invests in an actively managed, high quality portfolio consisting of 15 financial services companies made up of Canadian and U.S. issuers as follows:Bank of Montreal National Bank of Canada Bank of America Corp.The Bank of Nova Scotia Manulife Financial Corporation Citigroup Inc.Canadian...

Continue reading

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in advanced solid tumors unresponsive to established treatmentsThe observed tumor control rate of 36% in the low and mid-dose cohorts (n=14) in patients with advanced metastatic cancer further enhances our confidence in MDNA11’s monotherapy activity, consistent with our belief in its potential to selectively bolster cancer-fighting immune cellsFifth dose-escalation cohort is currently enrolling patients with no dose-limiting toxicities observed in the trial to-dateTORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology...

Continue reading

BYND Cannasoft Enterprises Inc. Launches Beta Test for Managing Farms CRM Platform at Israel’s Weizmann Institute of Science

Beta version of software provided as SAAS includes BYND Cannasoft’s proprietary C.R.M. System – Job Management (BENEFIT), as well as a module system for managing farms and greenhouses with varied crops (CANNASOFT) VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced that its subsidiary BYND – Beyond Solutions Ltd. has signed an agreement with the Weizmann Institute of Science for the use of its proprietary software. Under the terms of the agreement, the Weizmann Institute of Science will use a beta version of the software provided as SAAS. The beta version will include BYND Cannasoft Enterprises’ C.R.M. System – Job Management (BENEFIT), as well as a module system (CANNASOFT) for managing farms...

Continue reading

Datasea Reports Full Fiscal Year 2022 Financial Results with Record Sales Orders and Revenue

BEIJING, Sept. 28, 2022 (GLOBE NEWSWIRE) — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), incorporated in Nevada in September 2014, is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city in China, today announced financial results for its full fiscal year ended June 30, 2022, and provided an update on its key strategic and operational initiatives. The Company will host a conference call and webcast to discuss its financial results today at 9 a.m. ET (9 p.m. Beijing and Hong Kong Time). “This year marked an important moment in Datasea’s history. We launched 5G messaging solutions and introduced acoustic intelligence to the market, which combined with our original smart city offerings, broadened the ecosystem and expanded the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.